Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TPMT | P51580 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11960067 | 0.77 | STAT3 (0.42) | ALDH1A1 | |
| SCHEMBL14307034 | 0.74 | ERN1 (0.38) | ALDH1A1MRGPRX1ERN1TSHRTPMT | |
| SCHEMBL19388929 | 0.73 | MEN1 (0.48) | ALDH1A1MRGPRX1ERN1TSHRTPMT | |
| SCHEMBL4641824 | 0.70 | TRPA1 (0.44) | ALDH1A1TSHR | |
| SCHEMBL3584509 | 0.69 | ALDH1A1 (0.45) | ALDH1A1ERN1TACR1TSHRNOS2 | |
| SCHEMBL9702496 | 0.69 | ALDH1A1 (0.45) | ALDH1A1ERN1TACR1TSHRNOS2 | |
| SCHEMBL27920866 | 0.69 | ALDH1A1 (0.39) | ALDH1A1ERN1TACR1TSHRTPMT | |
| SCHEMBL13677507 | 0.67 | ALDH1A1 (0.43) | ALDH1A1ERN1TACR1TSHRNOS2 | |
| SCHEMBL14469274 | 0.67 | ALDH1A1 (0.43) | ALDH1A1ERN1TACR1TSHRNOS2 | |
| SCHEMBL1721607 | 0.67 | ALDH1A1 (0.43) | ALDH1A1ERN1TACR1TSHRNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-12-14 | — | — | US | disclosed |
| US-9771592-B2 | Methods and compositions for treating or preventing pruritis | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MERCK SHARP & DOHME CORP. | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355997-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | ALDH1A1 2589/4885MRGPRX1 37/4885ERN1 4162/4885 |
| US-20080027095-A1 | Use Of 3-Substituted-2-(Diphenylmethy)-1-Azabicyclo[2.2.2]Octanes For Treating Mrg-X1 Receptor Mediated Diseases | MRGPRX1, MRGPRX2, MRGPRX4 | ALDH1A1 2071/4885MRGPRX1 1/4885ERN1 4034/4885 |
| US-20140303231-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | ALDH1A1 2589/4885MRGPRX1 37/4885ERN1 4162/4885 |
| US-20120073001-A1 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING PRURITIS | ITCH, CCL11, CPA3 | ALDH1A1 2589/4885MRGPRX1 37/4885ERN1 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.